Analyst CornerAnalyst Corner—Inside the GLP-1 Boom in the US, with Madhav Pitaliya Madhav Pitaliya, Analyst September 1, 2024 Reasons to ReadWelcome to Analyst Corner! Every Sunday, a member of the Coresight Research team discusses upcoming or recent research and their thoughts on interesting topics in their area of expertise. This week, Madhav Pitaliya, Analyst at Coresight Research, discusses the state of the GLP-1 drug market in the US. Understand key data on obesity rates and recent sales results for weight-loss drugs in this free research report. We also highlight our key research from the past week and reports to look out for in the coming week, so you don’t miss out. Other relevant research: Decoding the GLP-1 Trend: How Is the Ozempic Economy Impacting CPG Retail? What the Ozempic Economy Means for US Retail Data Dive: The Global Obesity Economy—Shaped by the Spending of 1 Billion Consumers Read previous Analyst Corner reports, including last week’s report, which discusses headline data about China’s declining population. Please Login to read the full report. Not a member? To access this content for free, register for a free account. This document was generated for Other research you may be interested in: Three Data Points We’re Watching This Week, Week 33: US Consumers’ Tariff PerceptionsEssential Guide to Groceryshop 2025: Harnessing AI, Shopper Insights and Retail Media to Build Future-Ready CommerceMay 2025 US Retail Sales Outlook: Projecting 3% Growth Amid Low Sentiment and Front-Loaded PurchasesWeekly US Store Openings and Closures Tracker 2025, Week 16: 7-Eleven To Close 300+ Stores; Plus Updates on Drugstore Closures